::: SenoRx ::: About SenoRx

SenoRx was founded in 1998 to design, develop, manufacture and market minimally invasive devices for the diagnosis and treatment of breast cancer. Since its founding, SenoRx has developed multiple, proprietary technology platforms and a unique product portfolio that address the entire range of diagnostic and therapeutic procedures. It is the goal of SenoRx to become the leader in the marketplace by offering products and procedures that dramatically enhance patient outcomes.

SenoRx (NASDAQ: SENO), which completed its initial public offering of common stock in March 2007, develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis of breast cancer. SenoRx’s field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. With 17 products that have already received FDA 510(k) clearance across the continuum of breast care, SenoRx is developing additional minimally invasive products for diagnosis and treatment of breast cancer.

SenoRx has a strong portfolio of intellectual property. The company currently has 43 issued United States patents primarily covering devices relating to breast biopsy, including biopsy site marking devices, excision devices, and balloon products, and a total of 13 granted national patents from eight different European countries. In addition, SenoRx has 66 pending United States patent applications and 19 pending European patent applications.